• Explore /
  • Poster
  • / Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.

Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.

Abstract Poster

Authors

null

Benoist Chibaudel

Institut Hospitalier Franco-Britannique, Levallois-Perret, France

Benoist Chibaudel , Thierry Andre , Benoit Samson , Marie-Line Garcia-Larnicol , Jérôme Dauba , Gerard Lledo , Olivier Jean Marie Dupuis , Yves Rinaldi , May Mabro , Nathalie Aucoin , Frédéric Viret , Nicole Tubiana-Mathieu , Ahmed Khalil Sr., Ghaouti Nabil Baba Hamed , Werner Scheithauer , Elisabeth Carola , Dewi Vernerey , Christophe Louvet , Aimery De Gramont , Christophe Tournigand

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00265824

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 737)

DOI

10.1200/JCO.2018.36.4_suppl.737

Abstract #

737

Poster Bd #

J3

Abstract Disclosures

Similar Posters

First Author: Benoit Samson

First Author: Lisa Miller-Phillips

First Author: Matthew E. Burge

First Author: David Chan